A_phase_II_study_of_days_1_and_8_cisplatin_and_recombinant_alpha-2B_interferon_in_advanced_non-small_cell_lung_cancer._Preclinical_data_from_studies_of_human_lung_cancer_xenografts_suggest_that_the_cytotoxic_effects_of_cisplatin_are_enhanced_by_alpha-interferon._To_verify_the_above_observations,_the_authors_initiated_a_Phase_II_trial_in_advanced_non-small_cell_lung_cancer_(NSCLC)._Cisplatin_was_given_at_100_mg/m2_during_a_28-day_cycle_in_a_divided_day_1_and_day_8_schedule._Starting_on_day_1,_alpha-2B_interferon_was_administered_intramuscularly_at_a_dose_of_5_million_units_three_times_a_week_continuously_for_a_minimum_of_2_months._Between_January_1989_and_September_1989,_30_patients_were_evaluated_for_response_and_toxicity._According_to_the_staging_system_proposed_by_Mountain,_20_patients_had_Stage_IV_disease,_7_had_Stage_IIIB_disease,_and_3_had_Stage_IIIA_disease._Expression_of_neuron-specific_enolase_(NSE)_and_Leu-7_was_immunohistochemically_investigated_to_evaluate_possible_relationship_to_treatment_response._The_response_rate_was_13.3%_(95%_confidence_interval_CI:_1.2%_to_25%)._The_four_responders_showed_positivity_for_NSE,_and_two_of_them_were_positive_for_Leu-7._An_average_of_three_cycles_was_given._The_mean_dose_intensity_administered_was_83%_of_the_projected_dose_for_cisplatin_and_92%_of_the_projected_dose_for_alpha-2B_interferon._A_standard_scale_was_used_to_assess_interferon_toxicity._Hematologic,_renal,_and_systemic_side_effects_were_not_significant._In_advanced_NSCLC_the_addition_of_alpha-2B_interferon_did_not_increase_the_cisplatin-induced_response_rate._Further_studies_should_be_performed_to_determine_the_real_value_of_chemotherapy_response_in_tumors_showing_positive_immunoreactivity_for_neural_markers_such_as_NSE_and_Leu-7.